Shire Will Be Bought, Say Investors: StockTwits.com

NEW YORK (TheStreet) -- Investors say AbbVie's  (ABBV) pursuit of Irish drug company Shire (SHPG) won't end like Pfizer's  (PFE) failed bid for AstraZeneca  (AZN).

On StockTwits.com, investors bet that Shire's Friday morning rejection of AbbVie's $46.3 billion bid for the foreign pharmaceutical company would be met with a higher bid -- if not from AbbVie than another pharmaceutical company. Allergan (AGN) was the most discussed potential suitor on the site. The stock rose 16% on Friday.

$SHPG Was previously rumored that $AGN approached them; 6/16 we heard $SHPG hired an adviser to deal with takeover offers

? Open Outcrier (@openoutcrier) Jun. 20 at 08:31 AM

Imminent bid expected for $SHPG from $AGN to fend off $VRX bid. Wow, call it "acquisition roulette." http://stks.co/h0jQt

? Pierce Crosby (@CrosbyVenture) Jun. 18 at 10:04 AM

The rejection comes in the wake of Pfizer's failed $118 billion merger with the UK's AstraZeneca. U.S. drug companies have pursued smaller foreign competitors in hopes of increasing scale and taking advantage of more favorable corporate tax laws in places like Ireland. Corporations in the U.S. currently pay 35%, according to Deloitte. In Shire's hometown of Dublin, the income tax rate is 12.5%.

Shire management said Friday that AbbVie's bid significantly undervalued the company. The company said that the 23% premium AbbVie offered to its closing share price on June 19 "fundamentally undervalued" its prospects to be a leader in the rare disease and specialty markets. In addition to drugs like Adderal XR, the company has about 17 compounds in various human trial stages that focus on rare diseases.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst